Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-02-19 |
2024-01 |
0 |
N/A |
N/A |
N/A |
2023-11-06 |
2023-07 |
0 |
N/A |
N/A |
N/A |
2023-08-02 |
2023-04 |
0 |
N/A |
N/A |
N/A |
2023-05-04 |
2023-01 |
0 |
N/A |
N/A |
N/A |
2023-02-13 |
2022-10 |
0 |
N/A |
N/A |
N/A |
2022-09-12 |
2022-07 |
0 |
-3.83 |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2020-11-25 |
H.C. Wainwright |
Downgrade |
Buy |
Neutral |
2020-11-25 |
Jefferies |
Downgrade |
Buy |
Hold |
2020-11-25 |
H.C. Wainwright |
Upgrade |
Buy |
Buy |
2020-11-25 |
Cantor Fitzgerald |
Upgrade |
Overweight |
Overweight |
2020-11-25 |
Barclays |
Upgrade |
|
Overweight |
2020-11-25 |
Barclays |
Upgrade |
|
Overweight |
Date |
Name |
Relation |
Quantity |
Description |
2020-03-12 |
APPEL RONI A |
Director |
0.00 |
Sale |
2019-04-07 |
BERLIN KENNETH A |
Chief Executive Officer |
4.00K |
Stock Award(Grant) |
2018-06-25 |
BERMAN RICHARD J |
Director |
55.67K |
Stock Award(Grant) |
2018-03-28 |
BONSTEIN SARA M |
Chief Financial Officer |
226.67K |
Stock Award(Grant) |
2019-04-10 |
GUTIERREZ ANDRES A. |
Officer |
3.75K |
Stock Award(Grant) |
2019-04-10 |
HENDERSON MOLLY |
Chief Financial Officer |
5.83K |
Stock Award(Grant) |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2021-09-29 |
Vanguard Group, Inc. (The) |
5.96M |
3.11M |
4.09% |
2021-09-29 |
Blackrock Inc. |
1.26M |
655.66K |
0.86% |
2021-09-29 |
Geode Capital Management, LLC |
1.14M |
592.18K |
0.78% |
2021-09-29 |
State Street Corporation |
385.06K |
200.81K |
0.26% |
2021-09-29 |
Northern Trust Corporation |
252.88K |
131.88K |
0.17% |
2021-09-29 |
Millennium Management LLC |
244.97K |
127.75K |
0.17% |
Report Date |
Organization |
Position |
Value |
Percentage |
2021-09-29 |
Vanguard Total Stock Market Index Fund |
4.10M |
2.14M |
2.82% |
2021-09-29 |
Vanguard Extended Market Index Fund |
1.66M |
867.68K |
1.14% |
2021-10-30 |
Fidelity Extended Market Index Fund |
753.76K |
365.27K |
0.52% |
2021-09-29 |
Price (T.Rowe) U.S. Equities Trust |
166.75K |
86.96K |
0.11% |
2021-10-30 |
iShares Core S&P Total U.S. Stock Market ETF |
159.79K |
77.43K |
0.11% |
2021-10-30 |
Fidelity NASDAQ Composite Index Fund |
132.08K |
64.01K |
0.09% |
Split |
Date |
1 : 80 |
2022-06-06 |
1 : 15 |
2019-03-29 |
0.008 : 1 |
2013-07-15 |